NCT04963920

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock

• Status: Suspended
• Phase: N/A
• Study type: Interventional
• Enrollment: 260 (estimated)
• Sponsor: CytoSorbents Europe GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with vasoplegic septic shock.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DEVICE	Cytosorb® 300 ml	patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines

Timeline

• Start date: 2022-01-30
• Primary completion: 2027-02-01
• Completion: 2027-05-01
• First posted: 2021-07-15
• Last updated: 2025-08-05

Locations

18 sites across 1 country: Germany